Detalhe da pesquisa
1.
Insulin receptor alternative splicing in breast and prostate cancer.
Cancer Cell Int
; 24(1): 62, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38331804
2.
RNA-binding protein CUGBP1 controls the differential INSR splicing in molecular subtypes of breast cancer cells and affects cell aggressiveness.
Carcinogenesis
; 41(9): 1294-1305, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31958132
3.
TIAM1 Upregulation Confers NVP-BEZ235 Resistance to Breast Cancer Cells Through FGFR/STAT3 Pathway.
Biochem Genet
; 58(6): 953-965, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32671511
4.
Identification of differentially expressed genes-related prognostic risk model for survival prediction in breast carcinoma patients.
Aging (Albany NY)
; 13(12): 16577-16599, 2021 06 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175839
5.
PRAS40 hyperexpression promotes hepatocarcinogenesis.
EBioMedicine
; 51: 102604, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31901857
6.
Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Cancer Lett
; 475: 53-64, 2020 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32006616
7.
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer.
Onco Targets Ther
; 10: 1735-1742, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28356761
8.
Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1.
Biomed Pharmacother
; 95: 649-655, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881292
9.
The role of EphB4 and IGF-IR expression in breast cancer cells.
Int J Clin Exp Pathol
; 8(5): 5997-6004, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26191333
10.
Corrigendum to 'PRAS40 hyperexpression promotes hepatocarcinogenesis' [EBioMedicine 51 (2020) 102,604].
EBioMedicine
; 60: 103001, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32979837